Blood cancers

MCL2: prolonged remissions without survival plateau

The latest data from the long-running Second Nordic Mantle Cell Lymphoma (MCL2) trial suggests that the disease will not be eradicated by strategies that are currently considered first line treatment, experts say. The 15-year updated results of the study involving 159 patients aged under 66 followed for a median of 11.4 years revealed that half of ...

Already a member?

Login to keep reading.

© 2021 the limbic